Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Eli Lilly and Company shared data today seemingly confirming the superior weight loss qualities of its tirzepatide GLP-1 agonist over semaglutide from rival Novo Nordisk A/S. Eli Lilly and Novo Nor...
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's (LLY) popular weight-loss drug Zepbound outperformed Wegovy, a competitor drug from Danish drugmaker Novo Nordisk (NVO), according to the results of a new clinical study released Wednes...
Eli Lilly's Weight-Loss Drug Zepbound Is Better than Novo's Wegovy, Study Finds
On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy, Lilly said.
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-de...
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings sug...
Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Eli Lilly investors have suffered an unexpected bear market as recent headwinds buffeted the stock. Notwithstanding near-term execution challenges, Lilly's weight loss drugs are gaining more share....
The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now
Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue growth thanks to the fact that patients need their medicines -- so will con...
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs
Eli Lilly (LLY) and Novo Nordisk (NVO) shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' popular weight-loss drugs in government-backed healthcare pla...
Eli Lilly: Steep Pullback, Still Compelling Here
LLY's recent sell-off has been unwarranted indeed, since the lowered FY2024 guidance is attributed to the complexities of inventory management and non-cash/ one-time IPR&D charges. Even so, the pul...
Billionaire Israel Englander Increased His Stake In Eli Lilly During the Third Quarter: Should You?
After flying high during the first half of the year, pharmaceutical giant Eli Lilly (LLY -0.26%) has lost some momentum; the company's shares are down by 11% since June 1. However, the healthcare l...
2 Incredible Growth Stocks to Buy With $1,000 Right Now
2 Incredible Growth Stocks to Buy With $1,000 Right Now
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal...
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an ...
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now
Related Companies